Moreover, some studies suggested that the addition of celecoxib to chemotherapy might adversely impact the prognosis of breast cancer patients, especially those with prostaglandin-endoperoxide synthase 2 (PTGS2) low tumors (NCT01041781) [301]. Here, PTGS2 is linked to breast cancer.